Under the new cross-licensing arrangement, Caliper acquires the right to sublicense AntiCancer’s fluorescent protein optical imaging patents to third-parties, alongside Caliper’s own portfolio of in vivo fluorescent and bioluminescent optical imaging patents. AntiCancer acquires the right to sublicense Caliper’s optical imaging patents, in the field of fluorescent protein imaging, to a specified annual number of third parties throughout the life of the agreement, alongside AntiCancer’s own fluorescent protein optical imaging patents. In addition, each company receives a royalty free license from the other for internal and contract research operations.
The agreement further strengthens Caliper’s intellectual property estate specifically extending the range of fluorescent protein optical imaging rights available to customers. Under the cross-license arrangement, Caliper and AntiCancer will share in any revenues generated by the licensing of their proprietary imaging technologies in the field of fluorescent protein imaging. No other payments will be made for either the settlement or cross-licensing agreements. The companies also expect to enter into an OEM distribution agreement under which Caliper will market and sell certain mouse and cell lines developed by AntiCancer for use in fluorescent protein-based optical imaging experiments.
Kevin Hrusovsky, president and CEO of Caliper, said: “This settlement and the resulting alignment between Caliper and AntiCancer represent a major step forward for the in vivo molecular imaging community. We look forward to the opportunity to expand our reagents business by marketing and selling fluorescent protein cell lines developed by AntiCancer.”